The PINK1-Parkin mitophagy pathway is a critical mitochondrial quality control mechanism that is dysfunctional in early-onset Parkinson's disease (PD). The pathway involves PINK1 (PTEN-induced kinase 1), a mitochondrial serine/threonine-protein kinase, and Parkin, an E3 ubiquitin ligase. Together, they coordinate the selective removal of damaged mitochondria through mitophagy [1][2]. [1]
This pathway is one of the most important mechanistic links between mitochondrial dysfunction and dopaminergic neuron loss in PD, explaining why toxins that impair mitochondria (MPTP, rotenone) can replicate PD pathology [3]. [2]
PINK1 is encoded by the PINK1 gene (chromosome 1p36), a 581-amino acid protein with kinase activity that localizes to mitochondria and functions as a sensor of mitochondrial health [4]. [3]
| Feature | Details |
|---|---|
| Gene | PINK1 (PARK6) |
| Chromosome | 1p36.22 |
| Protein size | 581 amino acids |
| Mass | ~63 kDa |
| Subcellular location | Mitochondria (outer membrane when activated) |
| Kinase domain | Serine/Threonine |
| Key phosphorylation sites | Ser228, Ser402 |
Parkin is encoded by the PRKN gene (chromosome 6q26), a 465-amino acid protein belonging to the RBR (Ring-Between-Ring) family of E3 ubiquitin ligases. It is typically inactive in the cytosol until recruited to damaged mitochondria [5].
| Feature | Details |
|---|---|
| Gene | PRKN (PARK2) |
| Chromosome | 6q26 |
| Protein size | 465 amino acids |
| Mass | ~52 kDa |
| Structure | RING0, RING1, IBR, RING2 domains |
| E3 ligase activity | Activated by phosphorylation |
| Protein | Domains | Function |
|---|---|---|
| PINK1 | N-terminal mitochondrial targeting, kinase domain (C-terminal) | Sensor of mitochondrial damage, autophosphorylates on activation |
| Parkin | RING0 (ubiquitin-binding), RING1 (E2 binding), IBR (between RING), RING2 (catalytic) | E3 ubiquitin ligase, ubiquitinates OMM proteins |
Under normal conditions, PINK1 is imported into mitochondria via the TOM/TIM translocases and degraded by proteases (PARL, OMA1). When mitochondria sustain damage:
PINK1 acts as both kinase and scaffold:
Activated Parkin ubiquitinates multiple OMM proteins:
| Target | Ubiquitin Chain Type | Function |
|---|---|---|
| Mitofusin 1/2 (MFN1/2) | K63-linked | Marks for degradation, prevents fusion |
| VDAC1 | K63-linked | Permeability, recruits p62 |
| TOM complex | K27-linked | Import machinery |
| Miro1 | K48-linked | Mitochondrial transport |
| USP30 | K6-linked | Deubiquitinase, counteracts Parkin [6] |
| Mutation | Effect | Type | Frequency |
|---|---|---|---|
| G309D | Kinase domain impairment | Missense | Common |
| L347P | Kinase domain impairment | Missense | Common |
| W437X | Truncation | Nonsense | Less common |
| Q456X | Truncation | Nonsense | Rare |
| A168P | Kinase domain | Missense | Rare |
Inheritance: Autosomal recessive
Phenotype: Early-onset PD (<40 years), dystonia, excellent levodopa response
| Gene | Protein | Interaction |
|---|---|---|
| PARK7 (DJ-1) | DJ-1 | Essential downstream mediator [7] |
| ATP13A9 | ATP13A9 | Lysosomal function, interacts with PINK1 |
| USP30 | USP30 | Mitochondrial deubiquitinase, counteracts Parkin [6] |
Loss-of-function mutations in PINK1 or Parkin lead to:
Recent research shows Parkin deletion exacerbates neuroinflammation [8]:
Recent evidence shows bidirectional relationship [10]:
| Approach | Status | Description |
|---|---|---|
| AAV-PINK1 | Preclinical | Deliver functional PINK1 gene |
| AAV-Parkin | Preclinical | Restore Parkin expression |
| CRISPR editing | Research | Correct mutations |
| Molecular glues | Research | Enhance Parkin activation [11] |
| Agent | Target | Status |
|---|---|---|
| Natrin | PINK1 | Preclinical |
| K351 | Parkin | Preclinical |
| Speamycin A | UCH-L1 | Research |
| USP30 inhibitors | USP30 | Preclinical [12] |
| Agent | Mechanism | Status |
|---|---|---|
| Rapamycin | mTOR inhibition | Clinical trials |
| Lithium | Autophagy enhancement | Research |
| Urolithin A | Mitophagy inducer | Phase 2 trials |
| Salidroside | PINK1/Parkin enhancement [13] | Preclinical |
| Biomarker | Target | Sample | Utility |
|---|---|---|---|
| PINK1 mRNA | Expression | Blood | Risk stratification |
| Parkin activity | Enzyme function | Lymphocytes | Disease progression |
| Phospho-ubiquitin | Pathway activation | Skin fibroblasts | Treatment response |
| Mitochondrial DNA | Circulating mtDNA | Plasma | Mitochondrial health |
| p62 levels | Autophagy markers | CSF | Disease severity |
Sauvé V et al. A molecular glue for PRKN/parkin. Autophagy. 2025. 2025. ↩︎
Kuang E et al. Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson's disease mouse model. Nat Rev Neurosci. 2024. 2024. ↩︎
Zhang L et al. Salidroside Protects Dopaminergic Neurons by Enhancing PINK1/Parkin-Mediated Mitophagy. Free Radic Biol Med. 2020. 2020. ↩︎